$4.82
14.76% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US8883143096
Symbol
TTNP

Titan Pharmaceuticals, Inc. Stock price

$4.82
+0.32 7.11% 1M
+0.68 16.43% 6M
+1.56 47.85% YTD
-0.69 12.52% 1Y
-22.98 82.66% 3Y
-173.98 97.30% 5Y
-574,393.18 100.00% 10Y
+2.77 135.12% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.62 14.76%
ISIN
US8883143096
Symbol
TTNP
Industry

Key metrics

Basic
Market capitalization
$5.6m
Enterprise Value
$3.6m
Net debt
positive
Cash
$2.0m
Shares outstanding
910.0k
Valuation (TTM | estimate)
P/E
- | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
83.6%
Return on Equity
-192.9%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -
Net Income
- | -
Free Cash Flow
$-4.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -
Net Income
- | -
Free Cash Flow
28.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-4.5
Short interest
0.9%
Employees
4
Rev per Employee
$0.0
Show more

Is Titan Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Titan Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Titan Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.56 4.56
18% 18%
-
- Research and Development Expense - -
-
-
-4.55 -4.55
37% 37%
-
- Depreciation and Amortization 0.01 0.01
91% 91%
-
EBIT (Operating Income) EBIT -4.56 -4.56
37% 37%
-
Net Profit -4.71 -4.71
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Titan Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Titan Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
7 days ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Titan Pharmaceuticals, Inc. (the “Company”) (NasdaqCM: TTNP) and KE Sdn. Bhd. Under the terms of the proposed transaction, shareholders of Titan are expected to own approximately 13.3% of the combined company. K...
Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company's newly designated Series C Convertible Preferred Stock (the “Preferred Stoc...
Neutral
GlobeNewsWire
2 months ago
NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) (“TalenTec”), which includes Titan'...
More Titan Pharmaceuticals, Inc. News

Company Profile

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Head office United States
CEO Mr. Chay
Employees 4
Founded 1992
Website www.titanpharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today